10-Q: PURE Bioscience Q3 2026 Results Show Revenue Growth Amidst Net Loss

PURE Bioscience reports increased net product sales for Q3 2026 compared to the prior year, though the company continues to operate at a net loss and faces going concern uncertainties.

Summary

• PURE Bioscience reported net product sales of $506,000 for the three months ended April 30, 2026, an increase from $489,000 in the same period of 2025.
• For the nine months ended April 30, 2026, net product sales were $1,656,000, up from $1,435,000 in the comparable period of 2025.
• The company experienced a net loss of $624,000 for the three months ended April 30, 2026, compared to a net loss of $580,000 for the same period in 2025.
• The net loss for the nine months ended April 30, 2026, was $1,873,000, an improvement from $2,067,000 in the nine months ended April 30, 2025.
• As of April 30, 2026, the company had $983,000 in cash and cash equivalents, an increase from $334,000 as of July 31, 2025.
• The company has a stockholder deficiency of $5,839,000 as of April 30, 2026, and its independent auditors have expressed substantial doubt about its ability to continue as a going concern.
• A private placement financing on April 30, 2026, raised $1.0 million through the issuance of 18,131,096 shares of common stock at $0.0553 per share.
• Robert Bartlett will retire as CEO effective August 1, 2026, and will be succeeded by Jeffrey Kitchell, currently President.
• Bernard Blotner resigned as a member of the Board of Directors, effective June 11, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautiously negative sentiment due to the continued net losses and going concern warnings, despite positive revenue trends and a recent capital raise.

Positives

• Net product sales increased by $17,000 (3.5%) to $506,000 for the three months ended April 30, 2026, compared to the prior year period, driven by increased sales across the distribution network.
• Net product sales for the nine months ended April 30, 2026, increased by $221,000 (15.4%) to $1,656,000 compared to the prior year period, attributed to increased sales across the end-user network.
• Gross margin percentage for the nine months ended April 30, 2026, remained stable at 58%, consistent with the prior year.
• Cash and cash equivalents increased to $983,000 as of April 30, 2026, from $334,000 as of July 31, 2025, due to financing activities.
• The company successfully raised $1.0 million in a private placement financing on April 30, 2026.
• The company's net loss for the nine months ended April 30, 2026, decreased by $194,000 to $1,873,000 from $2,067,000 in the prior year period.

Negatives

• The company incurred a net loss of $624,000 for the three months ended April 30, 2026, and $1,873,000 for the nine months ended April 30, 2026.
• The gross margin percentage decreased to 53% for the three months ended April 30, 2026, from 57% in the prior year period, due to increased sales of lower-margin product configurations.
• Total liabilities increased to $7,397,000 as of April 30, 2026, from $6,174,000 as of July 31, 2025, primarily due to convertible notes payable.
• The company has a stockholder deficiency of $5,839,000 as of April 30, 2026.
• The company used $1,324,000 in operating activities during the nine months ended April 30, 2026.
• Interest expense increased to $106,000 for the three months ended April 30, 2026, from $78,000 in the prior year period, and to $301,000 for the nine months ended April 30, 2026, from $210,000 in the prior year period, due to accrued interest on convertible notes.

Risks

• The company has a history of recurring losses and a stockholder deficiency, raising substantial doubt about its ability to continue as a going concern.
• Existing cash resources are not sufficient to meet anticipated needs over the next twelve months, requiring additional capital which may not be available on acceptable terms.
• Failure to obtain additional capital could lead to delays or scaling back of marketing, distribution, and commercialization activities, or cessation of operations.
• Issuance of additional equity securities to raise funds would likely result in substantial dilution to existing stockholders.
• Debt financing could impose significant cash payment obligations and restrictive covenants.
• Concentration of revenue from a single customer (21% for the nine months ended April 30, 2026) poses a risk if that customer's business is negatively impacted.
• Concentration of accounts receivable from a few customers (14% from one customer as of April 30, 2026) could impact cash flow if not collected.
• Reliance on a few key vendors for purchases (29% and 13% for the nine months ended April 30, 2026) could pose supply chain risks.
• The company's ability to successfully complete in-plant validation trials and convert them into customer orders is critical.
• Obtaining necessary regulatory approvals, including USDA approvals, involves costs and time.

Future Outlook

The company's future capital requirements depend on product acceptance, sales success, regulatory approvals, further product development, and operational costs. Until positive cash flow from operations is generated, the company will rely on equity and debt offerings, which may result in dilution or restrictive terms. Insufficient funds could lead to scaled-back operations or cessation.

Management Comments

• "Our technology platform is based on patented stabilized ionic silver, and our initial products contain Silver Dihydrogen Citrate, or SDC. This broad-spectrum, non-toxic antimicrobial agent is available in liquid form and various concentrations, distinguished by its superior efficacy, reduced toxicity, non-causticity, and the inability of bacteria to develop resistance."
• "We see significant market opportunities for our safe and effective SDC-based solutions, particularly in the food industry."
• "Until the Company can continually generate positive cash flow from operations, it will need to continue to fund its operations with the proceeds of offerings of our equity and debt securities."
• "If we raise additional funds from the issuance of equity securities, substantial dilution to its existing stockholders would likely result."

Industry Context

StockSavvy.ai notes that PURE Bioscience operates in the antimicrobial and food safety sector, a market driven by increasing concerns over hygiene, foodborne illnesses, and regulatory compliance. The company's SDC technology positions it to compete with traditional disinfectants and sanitizers, but faces challenges related to market adoption, competition, and the need for continuous innovation and regulatory adherence.

Comparison to Industry Standards

• The company's gross margin of 58% for the nine months ended April 30, 2026, is within a typical range for specialty chemical manufacturers, though specific comparisons depend on product lines and scale.
• The net loss reported is common for early-stage or growth-phase companies in the biotechnology and specialty chemical sectors that are investing heavily in R&D and market penetration.
• The company's reliance on external financing for operations is a standard practice for many companies in these capital-intensive industries, but the terms and availability of such financing are critical benchmarks.

Management Changes

Legal Proceedings

• The company is not currently aware of any legal proceedings or claims that would have a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• Messrs. Tom Y. Lee and Ivan Chen, members of the Board, invested in convertible promissory notes through affiliates or directly in private placements in fiscal years 2023, 2024, 2025, and 2026.
• Tom Y. Lee invested $1,000,000 in the 2023 Private Placement, $1,785,000 in the 2024 Private Placement, $2,000,000 in the 2025 Private Placement, and $970,000 in the 2026 Private Placement.
• Ivan Chen invested $15,000 in the 2023 Private Placement and $27,650 in the April 30, 2026 private placement financing.
• As of April 30, 2026, accounts payable include $235,000 in board fees due to officers and directors.

Stakeholder Impact

• Shareholders may experience dilution if the company issues additional equity to fund operations.
• Creditors and noteholders face ongoing risk due to the company's going concern issues, though convertible notes offer potential equity upside.
• Employees and directors may be impacted by the CEO transition and the company's financial stability.
• Suppliers may face extended payment terms or risks if the company's financial situation deteriorates.

Next Steps

• Continue to grow and support the distribution network.
• Partner with third parties for international marketing approvals.
• Develop additional proprietary products and applications.
• Protect and enhance intellectual property.
• Utilize proceeds from the recent private placement for general corporate purposes, including R&D, administrative expenses, and working capital.
• Finalize employment agreement with incoming CEO Jeffrey Kitchell.

Key Dates

Recommendation

The company shows positive revenue growth and has secured additional financing, which are encouraging signs. However, the persistent net losses, significant stockholder deficiency, and the explicit going concern warning from auditors necessitate a cautious approach. The upcoming CEO transition adds another layer of uncertainty. A 'hold' recommendation reflects the balance between potential upside from revenue growth and the substantial risks associated with financial viability.

Keywords

PURE Bioscience, Form 10-Q, Quarterly Report, April 30 2026, SDC, Antimicrobial, Food Safety, Revenue, Net Loss, Going Concern, Financing, Convertible Notes, Stock Options, CEO Transition